{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:58:56Z","timestamp":1793177936381,"version":"4.5.0"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["por-journal.com"],"crossmark-restriction":true},"short-container-title":["Pathol. Oncol. Res."],"abstract":"<jats:p>Endocrine therapy has played an essential role in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2\u2212) breast cancer. With the continuous development of endocrine targeting drugs, especially the emergence of selective cyclin-dependent kinase (CDK4\/6) inhibitors, the overall survival time in patients with HR+HER2\u2212 advanced breast cancer has been greatly improved. Their adverse reactions also need more attention in response to the climbing number of CDK4\/6 inhibitors. The common side effects of CDK4\/6 inhibitors were hematological toxicity, diarrhea, and liver function damage. Skin toxicity related to CDK4\/6 inhibitors was rare. We describe herein our preliminary observation of one HR+HER2\u2212 advanced metastatic breast cancer patient diagnosed with vitiligo-like lesions after 10\u00a0months of taking Palbociclib. Hoping to share our experience to increase the clinician awareness of this unusual adverse and contribute to the information in the literature.<\/jats:p>","DOI":"10.3389\/pore.2023.1611115","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T14:02:37Z","timestamp":1688652157000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Vitiligo-like lesions induced by cyclin-dependent kinase 4\/6 inhibitor Palbociclib: a case report and literature review"],"prefix":"10.3389","volume":"29","author":[{"given":"Shan","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanjing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanrong","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA-Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with Ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"New Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of Abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: A randomized clinical trial","volume":"6","author":"Sledge","year":"2020","journal-title":"Jama Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(20)30165-3","article-title":"Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: Past, present, and future","volume":"395","author":"Spring","year":"2020","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/S1470-2045(19)30420-6","article-title":"Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: A systematic review and network meta-analysis","volume":"20","author":"Giuliano","year":"2019","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s40264-021-01071-1","article-title":"Emerging skin toxicities in patients with breast cancer treated with new cyclin-dependent kinase 4\/6 inhibitors: A systematic review","volume":"44","author":"Silvestri","year":"2021","journal-title":"Drug Safety"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e2022045","DOI":"10.5826\/dpc.1202a45","article-title":"Ribociclib-induced vitiligo: A case report","volume":"12","author":"Silvestre","year":"2022","journal-title":"Dermatol Pract Conce"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1111\/ajco.13585","article-title":"Drug induced vitiligo-like depigmentation from a CDK 4\/6 inhibitor","volume":"18","author":"Chan","year":"2022","journal-title":"Asia-Pac J Clin Onco"},{"key":"B9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.7453\/gahmj.2013.008","article-title":"The CARE guidelines: Consensus-based clinical case reporting guideline development","volume":"2","author":"Gagnier","year":"2013","journal-title":"BMJ Case Rep"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"New Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e248782","DOI":"10.1136\/bcr-2022-248782","article-title":"Ribociclib-induced extensive vitiligo-like lesions: Possible pathomechanisms with clinical, dermoscopic and histological correlation","volume":"15","author":"Anjaneyan","year":"2022","journal-title":"BMJ Case Rep"},{"key":"B12","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1348\/000711299160077","article-title":"Coping with the disfiguring effects of vitiligo: A preliminary investigation into the effects of cognitive-behavioural therapy","volume":"72","author":"Papadopoulos","year":"1999","journal-title":"Br J Med Psychol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1097\/CAD.0000000000001350","article-title":"Venetoclax-induced vitiligo in a patient with chronic lymphocytic leukemia","volume":"33","author":"Abdeen","year":"2022","journal-title":"Anti-Cancer Drug"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.3892\/mmr.2018.9299","article-title":"Decreased SUMOylation of the retinoblastoma protein in keratinocytes during the pathogenesis of vitiligo","volume":"18","author":"Zhou","year":"2018","journal-title":"Mol Med Rep"},{"key":"B15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10549-020-05914-w","article-title":"Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors","volume":"185","author":"Sollena","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1111\/ijd.16356","article-title":"Vitiligo-like lesions induced by cyclin-dependent kinase 4\/6 inhibitor palbociclib","volume":"62","author":"Romagnuolo","year":"2023","journal-title":"Int J Dermatol"}],"container-title":["Pathology and Oncology Research"],"original-title":[],"link":[{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2023.1611115\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T14:02:39Z","timestamp":1688652159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2023.1611115\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,6]]},"references-count":16,"alternative-id":["10.3389\/pore.2023.1611115"],"URL":"https:\/\/doi.org\/10.3389\/pore.2023.1611115","relation":{},"ISSN":["1532-2807"],"issn-type":[{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,6]]},"article-number":"1611115"}}